Skip to main content
Bioera logo

Bioera — Investor Relations & Filings

Ticker · BIE ISIN · IT0005516130 LEI · 815600CE609AFE44D992 XMIL Manufacturing
Filings indexed 558 across all filing types
Latest filing 2024-12-31 Capital/Financing Update
Country IT Italy
Listing XMIL BIE

About Bioera

https://bioera.it/en/

Bioera S.p.A. is a company specializing in the production and distribution of natural and organic products. Its core business involves the development and marketing of a diverse portfolio that includes organic food, traditional food products, natural cosmetics, herbal remedies, and food supplements. The company focuses on providing consumers with products derived from natural sources, catering to the health and wellness market.

Recent filings

Filing Released Lang Actions
BIOERA SPA - Informativa al mercato ex art. 114 TUF al 30.11.2024
Capital/Financing Update Classification · 1% confidence The document is titled "Informativa al mercato ex art. 114 TUF al 30.11.2024" (Information to the market pursuant to art. 114 TUF as of 30.11.2024). Article 114 of the Italian Consolidated Financial Act (TUF) mandates listed companies to disclose specific information to the market, often related to financial health, especially when facing difficulties or significant events. The content details the Net Financial Indebtedness and overdue debt positions as of November 30, 2024, which is a periodic financial disclosure requirement mandated by regulation (Consob/TUF). This type of periodic disclosure, which is comprehensive but not the full annual report (10-K) or a standard quarterly report (IR), fits best under the category of 'Interim / Quarterly Report' (IR) if it were a standard financial statement release, or potentially a specific regulatory filing. However, given the specific nature of reporting on indebtedness and overdue payments under Article 114 TUF, it functions as a mandatory, periodic financial update shorter than a full annual report. Since the definitions do not explicitly cover 'Article 114 TUF Disclosure', we must choose the closest fit. It is a comprehensive financial update for an interim period (monthly data points provided, referencing the end of November). It is more detailed than a simple Earnings Release (ER) and is not a general announcement of a report (RPA). Therefore, 'Interim / Quarterly Report' (IR) is the most appropriate classification for this mandatory, periodic financial disclosure covering a period shorter than a year.
2024-12-31 Italian
BIOERA SPA - Informativa al mercato ex art. 114 TUF al 31/10/2024
Management Reports Classification · 1% confidence The document is explicitly titled "Informativa al mercato ai sensi dell'art. 114, comma 5, D.lgs. n. 58/98 ("TUF")" with a reference period of October 31, 2024. This type of mandatory disclosure in Italy, often referred to as a '114-bis communication' or similar, provides updates on key financial metrics like net financial debt and overdue payables, especially when the company is undergoing restructuring or facing financial distress (as evidenced by the detailed discussion of debt restructuring agreements, court proceedings, and creditor actions). This content aligns best with providing periodic financial and operational updates required by regulators, which is covered by the Interim / Quarterly Report (IR) category, as it is a comprehensive update for a specific period (October 31, 2024) that is not the full annual report (10-K). While it is a regulatory filing, 'IR' is more specific for periodic financial status updates than the general 'RNS'.
2024-11-30 Italian
BIOERA SPA - Deposito memoria udienza 14 novembre 2024
Legal Proceedings Report Classification · 1% confidence The document is a short regulatory announcement from BIOERA S.p.A. dated November 5, 2024. The subject ('Oggetto') is 'BIOERA SPA - Deposito memoria udienza 14 novembre 2024' (Filing of memorandum for the hearing on November 14, 2024). The text explicitly states that an authorized memorandum ('memoria autorizzata') was deposited regarding a debt restructuring agreement proceeding before the Tribunal of Milan. Since the document itself is an announcement about the filing/deposit of a legal document (a memorandum for a court hearing) and is very short (3170 characters), it fits the criteria for a general regulatory announcement rather than a specific report like an Audit Report (AR) or Legal Proceedings Report (LTR), although it relates to legal matters. Given the nature of providing updates on regulatory/legal steps that don't fit the specific LTR definition (which usually implies the outcome or detailed report of the proceedings), and its function as a brief market disclosure, the most appropriate general category is Regulatory Filings (RNS), as it is a mandatory disclosure of a procedural step. Alternatively, since it specifically concerns a legal proceeding (debt restructuring hearing), LTR (Legal Proceedings Report) is also a strong candidate. However, LTR usually implies the report *of* the proceedings or the legal document itself. This is an announcement *that* a document was filed. Given the options, RNS serves as the best general regulatory disclosure fallback for procedural updates that aren't detailed reports.
2024-11-05 Italian
BIOERA SPA - Informativa mensile POC ottobre 2024
Capital/Financing Update Classification · 1% confidence The document is titled "Informativa mensile al 31 ottobre 2024" (Monthly Information as of October 31, 2024) and provides detailed updates on a convertible bond loan ('Prestito') and related capital structure changes (subscriptions and conversions) as required by CONSOB Communication n. 1/23, referencing Article 114, paragraph 5 of Legislative Decree no. 58/1998. This structure—a comprehensive report detailing financial/capital status for a period shorter than a year (monthly update on a specific financial instrument)—aligns best with the definition of an Interim/Quarterly Report (IR), which covers comprehensive financial reporting for periods shorter than a year. Although it is a specific regulatory disclosure, its content is a detailed financial/capital status update, making IR more appropriate than the general 'RNS' or 'CAP' (which is usually for fundraising announcements, not ongoing status reports of existing instruments). The document is substantial (over 10,000 characters) and contains the full details, not just an announcement of the report's availability.
2024-11-04 Italian
BIOERA SPA - Informativa al mercato ex art. 114 TUF al 30 settembre 2024
Management Reports Classification · 1% confidence The document is titled "Informativa al mercato ex art. 114 TUF al 30 settembre 2024" (Information to the market pursuant to art. 114 TUF as of September 30, 2024). Article 114 of the Italian Consolidated Financial Act (TUF) mandates specific periodic disclosures, often related to financial position, especially when a company is under specific regulatory scrutiny or undergoing restructuring (as indicated by the mention of 'Accordi di Ristrutturazione dei Debiti' and 'CCII'). The content provides detailed financial metrics (Net Financial Debt, overdue payables) for the period ending September 30, 2024. This structure—a mandatory, periodic disclosure of key financial data outside of the full annual or quarterly report—is characteristic of an Interim/Quarterly Report (IR) or a specific regulatory disclosure. Since it focuses on key financial data for an interim period (Q3 2024) and is explicitly mandated by a specific article (114 TUF), it aligns best with the 'Interim / Quarterly Report' category (IR), which covers comprehensive financial reporting for periods shorter than a year. It is not a brief announcement (RPA) as the document contains substantial data tables and analysis, nor is it the full Annual Report (10-K).
2024-10-30 Italian
BIOERA SPA - Fissazione udienza discussione accordi ristrutturazione
Regulatory Filings Classification · 1% confidence The document is a formal announcement from BIOERA S.p.A. dated October 15, 2024, regarding the scheduling of a court hearing (November 14, 2024) to approve the company's debt restructuring agreement. This concerns significant legal and financial restructuring matters. It is not an Annual Report (10-K), an Earnings Release (ER), or a standard dividend notice. The content directly relates to legal proceedings concerning debt restructuring, which aligns best with the 'Legal Proceedings Report' (LTR) definition, as it is an update on a significant legal/regulatory matter involving the company's financial structure. Given the short length and the nature of the update, it is a specific regulatory disclosure, not a general fallback (RNS).
2024-10-15 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.